NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Being here on account of having a financial incentive or/and motive for hoping for NWBO not having its DCVax-L approved, we are all aware, that any period in your life, where due diligence and factual circumstances could've meant something to you, obviously must've been before your employment.as a paid shill.

I know the following will come as a chock to you, but try to brace yourself - or perhaps you could make yet a complaint for something that left your life miserable and you embraced ignorance.

Here's some basic introduction in the world of upcoming biotechs and how they all somehow once found themselves strugling with having no revenues, costs and dilution.

Asking ChatGBT

Can you tell me about biotechs who once only had one drug in pipeline and no revenue and had to dilute shares for many years, before getting approval and revenue and becoming a successfull biotech

Certainly! Here are a few examples of biotech companies that had only one drug in their pipeline, faced significant financial challenges, including diluting shares, before eventually achieving success:

Vertex Pharmaceuticals:

Initial Struggles: Vertex spent years focusing on developing treatments for cystic fibrosis. For a long time, they had no revenue from approved drugs and had to dilute shares to raise capital.
Turnaround: The approval of Kalydeco in 2012 marked a significant turning point. It was the first drug to treat the underlying cause of cystic fibrosis, rather than just the symptoms.
Success: Vertex now generates billions in revenue from its cystic fibrosis treatments and has a robust pipeline of other drugs.

Moderna:

Initial Struggles: Moderna focused on mRNA technology, which was unproven for many years. They had no approved products and had to raise funds through multiple rounds of financing, resulting in share dilution.
Turnaround: The development and approval of the COVID-19 vaccine in 2020 was a breakthrough.
Success: The vaccine generated massive revenue, making Moderna a household name and validating mRNA technology.

Regeneron Pharmaceuticals:

Initial Struggles: Regeneron spent over a decade developing its first drug, with little to no revenue and frequent share dilutions to fund research.
Turnaround: The approval of Eylea in 2011 for the treatment of age-related macular degeneration was a game-changer.
Success: Eylea became a blockbuster drug, and Regeneron has since developed several other successful therapies.
Nektar Therapeutics:

Initial Struggles: Nektar had several years of financial difficulties with only one drug in the pipeline and had to repeatedly issue new shares to stay afloat.
Turnaround: The approval of Adynovate for hemophilia A provided a much-needed boost.
Success: Nektar has since expanded its pipeline and formed key partnerships, significantly improving its financial position.

Alnylam Pharmaceuticals:

Initial Struggles: Alnylam focused on RNA interference (RNAi) technology, which was speculative for many years. The company had no approved products and had to dilute shares to continue funding its research.
Turnaround: The approval of Onpattro in 2018, the first RNAi therapeutic, marked a major milestone.
Success: Onpattro and subsequent RNAi therapies have brought in substantial revenue, establishing Alnylam as a leader in the field.

Northwest Biotherapeutics - being updated

Initial Struggles:
Turnaround:
Success:

These examples highlight the challenging journey many biotech companies face, often requiring significant financial sacrifices and perseverance before achieving commercial success.

Have yet a nice day bullshitting mate.